On May 6, 2024, Vertex Pharmaceuticals Incorporated (VRTX), a pharmaceutical company pioneering in the field of Cystic Fibrosis (CF), reported solid first-quarter results as the company saw progress in its R&D pipeline. Its net product revenues increased 13.3% year-over-year to $2.69 billion, while its non-GAAP operating income surged 48.1% from the prior-year quarter to $1.34 billion.
Additionally, its non-GAAP net income came in at $1.24 billion or $4.76 per common share, representing more than a 56% year-over-year increase. However, as of March 31, 2024, VRTX’s cash and cash equivalents and marketable securities amounted to $10.17 billion, down from $11.22 billion as of December 31, 2023.
